+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Early Phase 1
Age: 18Years - 40Years
All Genders
ID07007078

Pilot Study of Dihydroartemisinin to Treat Acne Vulgaris in Adults Aged 18 to 40

Led by Shanghai Zhongshan Hospital · Updated on 2025-06-05

60

Participants Needed

1

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating dihydroartemisinin DHA as a potential treatment for Acne Vulgaris in adults. The study aims to determine if DHA can improve acne severity by at least one grade after treatment. This early phase 1 trial focuses on adults diagnosed with Acne Vulgaris and seeks to understand how DHA may affect their symptoms over a three-month period. Participants will take DHA at a dose of 40 mg three times a day for 90 days. The treatment phase lasts for three months, during which participants will visit the clinic once every month for checkups and tests. This trial does not use masking or blinding and includes only one study group receiving the experimental drug. During the study, participants will undergo assessments including the Investigators Global Assessment IGA of acne severity before and immediately after treatment. Other measures include changes in the Global Acne Grading System GAGS score, counts of inflammatory and non-inflammatory lesions, the number of participants reaching low IGA scores, and serum total testosterone levels. These evaluations help researchers monitor how DHA affects acne and related factors over the 90-day treatment period.

CONDITIONS

Brief Title

Efficacy of Dihydroartemisinin for Treating Acne Vulgaris

Research Team

L

Lujuan GAO, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here